Vaxcyte’s $100 Million Shares Offering

Latham & Watkins represented the underwriters in the transaction.

Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, has announced the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 2,500,000 shares of common stock and pre-funded warrants to purchase 2,500,000 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of US$20 per share, and the pre-funded warrants are being sold at a public offering price of US$19.999 per underlying share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately US$100 million, before deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price per share.

BofA Securities, Inc., Jefferies LLC, Evercore Group L.L.C., Cantor Fitzgerald & Co., and Needham & Company, LLC acted as underwriters for the offering.

Latham & Watkins represented the underwriters in the transaction with a capital markets deal team led by Bay Area partner Brian Cuneo (Picture), with associate Raul Gonzalez. Advice was also provided on regulatory matters by Washington, D.C. associate Chad Jennings.

Involved fees earner: Brian Cuneo – Latham & Watkins; Raul Gonzalez – Latham & Watkins; Chad Jennings – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Bank of America Securities; Cantor Fitzgerald; Jefferies; Needham & Company;